The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...

Hims & Hers Health CEO Andrew Dudum said the company will continue to sell cheap weight-loss shots despite Novo Nordisk A/S ...

Despite Novo Nordisk (NVO) recently ending a partnership with Hims & Hers Health (NYSE:HIMS) to distribute its weight-loss ...

The timing is also interesting. GLP-1s are Novo Nordisk's biggest and fastest-growing revenue stream, and competition is heating up. Eli Lilly's Zepbound is gaining traction, compounded access is ...

Hims & Hers Health Inc. won’t back down from selling cheap weight-loss shots, its chief executive officer said one day after Novo Nordisk A/S abruptly ended its distribution partnership. “We’re upset ...

The companies engaged in an increasingly heated war of words on Monday following the drugmaker's decision to end a collaboration.

Andrew Dudum, who identifies as Palestinian-American, voiced support for the student protesters across US campuses on X. 'Moral courage > College degree,' the CEO, 35, wrote on Wednesday.

SAN FRANCISCO—Andrew Dudum, CEO of Hims & Hers Health Inc. (NYSE: HIMS), recently sold a significant portion of his holdings in the company.According to a filing with the Securities and Exchange ...

Hims & Hers CEO Andrew Dudum sells $2.27 million in stock. Open in App. Get 45% Off. Sign In; Free Sign Up ...

In a recent transaction, Andrew Dudum, CEO of Hims & Hers Health, Inc. (NYSE:HIMS), sold a total of $1,051,087 worth of company stock, according to a Form 4 filed with the Securities and Exchange ...

Andrew Dudum. Hims & Hers’ latest telehealth offering: online therapy sessions. After dabbling with group therapy during the pandemic, the telehealth company has decided to launch one-on-one ...

The CEO of male hair loss company HIMS has sparked furious backlash and threats of a boycott after he offered jobs to university students protesting in support of Palestine. Andrew Dudum, who ...